Abstract
Schizophrenia is a disorder with a pronounced developmental component. Accordingly, there is a growing interest in characterizing developmental changes in the period leading up to disease onset, in an effort to develop effective preventative interventions. One of the ongoing neurodevelopmental changes known to occur in the late adolescent period that often overlaps with the prodromal phase and time of onset is white matter development and myelination. In this critical review, a disruption in the normal trajectory of white matter development could potentially play an important role in the onset of psychosis. We seek to summarize the existing state of research on white matter development in prodromal subjects, with a particular focus on diffusion tensor imaging (DTI) measures. First, we describe the physiological basis of developmental white matter changes and myelination. Next, we characterize the pattern of white matter changes associated with typical development across adolescence as measured with DTI. Then, we discuss white matter changes observed in adult patients with schizophrenia and in individuals seen in genetic and clinical high risk states. Finally, we discuss the implications of these findings for future research directions and for potential therapeutic interventions.
Keywords: Schizophrenia, white matter, high-risk, development, adolescence, myelination, diffusion tensor imaging, neuroimaging, psychosis, isotropic diffusion
Current Pharmaceutical Design
Title: The Relationship of Developmental Changes in White Matter to the Onset of Psychosis
Volume: 18 Issue: 4
Author(s): Katherine H. Karlsgodt, Sarah C. Jacobson, Marc Seal and Paolo Fusar-Poli
Affiliation:
Keywords: Schizophrenia, white matter, high-risk, development, adolescence, myelination, diffusion tensor imaging, neuroimaging, psychosis, isotropic diffusion
Abstract: Schizophrenia is a disorder with a pronounced developmental component. Accordingly, there is a growing interest in characterizing developmental changes in the period leading up to disease onset, in an effort to develop effective preventative interventions. One of the ongoing neurodevelopmental changes known to occur in the late adolescent period that often overlaps with the prodromal phase and time of onset is white matter development and myelination. In this critical review, a disruption in the normal trajectory of white matter development could potentially play an important role in the onset of psychosis. We seek to summarize the existing state of research on white matter development in prodromal subjects, with a particular focus on diffusion tensor imaging (DTI) measures. First, we describe the physiological basis of developmental white matter changes and myelination. Next, we characterize the pattern of white matter changes associated with typical development across adolescence as measured with DTI. Then, we discuss white matter changes observed in adult patients with schizophrenia and in individuals seen in genetic and clinical high risk states. Finally, we discuss the implications of these findings for future research directions and for potential therapeutic interventions.
Export Options
About this article
Cite this article as:
H. Karlsgodt Katherine, C. Jacobson Sarah, Seal Marc and Fusar-Poli Paolo, The Relationship of Developmental Changes in White Matter to the Onset of Psychosis, Current Pharmaceutical Design 2012; 18(4) . https://dx.doi.org/10.2174/138161212799316073
| DOI https://dx.doi.org/10.2174/138161212799316073 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry WNT Signaling in Stem Cell Biology and Regenerative Medicine
Current Drug Targets Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders The Role of Neurotrophins in Axonal Growth, Guidance, and Regeneration
Current Neurovascular Research L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Activity-Dependent Neurorehabilitation Beyond Physical Trainings: “Mental Exercise” Through Mirror Neuron Activation
CNS & Neurological Disorders - Drug Targets The Gastrin-Releasing Peptide Receptor (GRPR) in the Spinal Cord as a Novel Pharmacological Target
Current Neuropharmacology Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Transcriptional Factors and Protein Biomarkers as Target Therapeutics in Traumatic Spinal Cord and Brain Injury
Current Neuropharmacology Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway
Current Signal Transduction Therapy Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Neurotrophin Receptor-Based Strategies for Alzheimers Disease
Current Alzheimer Research White Matter Injury Mechanisms
Current Molecular Medicine Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets




